Emma L McConnell

Dr. Emma L McConnell

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2020 in Ophthalmic and Physiological Optics
Verified
Journal Article
Open access
PDF file
EMEmma L McConnell
Emma L McConnell
KSKathryn J Saunders
Kathryn J Saunders
JLJulie‐Anne Little
Julie‐Anne Little
Purpose: Cerebral visual impairment (CVI) is the leading cause of childhood visual impairment in the developed world. Despite this, there are no agreed clinical guidelines for the investigation and diagnosis of the condition. Before development of such guidelines can commence, it is important to recognise which approaches are currently employed. This systematic review evaluated the literature to identify which methods of assessment are currently used to investigate and diagnose childhood CVI. Methods: Medline, Embase, CINAHL, Scopus and the Cochrane Library databases were systematically searched in January 2020 using defined search terms. Articles were included if they: (i) were research papers, conference abstracts or research protocols published in peer‐reviewed scientific journals, or relevant textbooks; (ii) included a clinical investigation of CVI in children; (iii) provided an explanation or criteria to diagnose CVI and (iv) were specifically investigating cerebral/cortical visual impairment. Methods used to a) assess and b) diagnose CVI were extracted from included articles. ‘Assessment scores’ were assigned for each method employed by researchers to investigate and diagnose CVI to quantify and compare approaches between articles. A quality grading was also applied to each article. Results: Of 6454 identified articles, 45 met the inclusion criteria. From these, 10 categories of assessment utilised within included articles were identified: (1) Medical history, (2) Vision assessment/ophthalmologic examination, (3) Neuroimaging, (4) Visual behaviour and direct observation, (5) Structured history‐taking, (6) Visual perception tests, (7) Ocular movement and posture assessment, (8) Intelligence/IQ assessment, (9) Clinical electrophysiology and (10) Neurodevelopmental tests. In terms of diagnostic criteria, the most commonly reported approach was one of exclusion, i.e., CVI was diagnosed when visual dysfunction could not be attributed to abnormalities detected in the anterior visual pathway. Conclusion: There is a lack of common practice in the approaches used by clinicians to investigate and diagnose CVI in children. At present, a ‘diagnosis of exclusion’ remains the most common means to diagnose CVI. Development of clinical guidelines for assessment and diagnosis are necessary to ensure consistency in the diagnosis of CVI and the timely implementation of support to alleviate the impact of CVI on the child’s daily living.

1 August 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SBS. A. Black
S. A. Black
EMEmma L McConnell
Emma L McConnell
LML. McKerr
L. McKerr
JMJ. F. McClelland
J. F. McClelland
JLJ. A. Little
J. A. Little
KSK. J. Saunders
K. J. Saunders
To determine whether implementation of comprehensive in-school eyecare results in measurable benefits for children and young people in terms of visual status, classroom behaviours and how well their visual needs are met. School-based observational study. 200 pupils [mean age 10 years 9 months, 70% male, majority moderate (40%) or severe (35%) learning difficulty] of a special education school in the UK. A sector-agreed in-school eyecare framework including full eye examination and cycloplegic refraction, dispensing of spectacles (as appropriate) and written reporting of outcomes to parents/teachers was applied. Classroom behaviours were observed and recorded prior to, and after, the in-school eyecare. Surveys were employed to obtain visual histories from parents/teachers. School records and statutory documents were reviewed for diagnostic and learning disability classifications. Visual function and ocular health were profiled at baseline and significant visual deficits identified. Where such deficits were previously unrecognised, untreated or not compensated for (e.g. correction of refractive error, enlargement of educational material) they were recorded as ‘unmet visual need’. At follow-up, 2–5 months after initial (baseline) measures, eye examinations, parent/teacher surveys and behaviour observations were repeated. Follow-up measures were used to determine if measurable improvements were evident in visual function, ocular health, the level of unmet need and classroom behaviour following implementation of in-school eyecare. 199 participants completed baseline and follow-up measures. 122 (61%) participants presented with at least one significant visual or ocular health deficit and 90 (45%) participants had at least one unmet visual need. Younger pupils and those with no previous history of eyecare were more likely to demonstrate unmet visual needs at baseline (OR 1.12 95% CI 1.03 to 1.21) p = 0.012; (OR 4.44 95% CI 1.38 to 14.29 p = 0.007 respectively). On follow-up, the number of pupils with unmet visual needs dropped significantly to 36 (18%) (McNemar’s test p0.05). Where significant refractive deficits were corrected at follow-up, near visual acuity improved significantly (Wilcoxon signed rank p = 0.013), however, poor spectacle compliance was a persistent cause of unmet visual need. Off-task behaviour reduced significantly after actions to address unmet visual needs were communicated to parents and teachers (Wilcoxon signed rank p = 0.035). The present study demonstrates for the first time measurable visual and behaviour benefits to children in special education settings when they receive comprehensive in-school eye examinations, on-site spectacle dispensing and jargon-free reporting of outcomes to teachers and parents.

20 June 2025 in American Journal of Ophthalmology
Verified
Journal Article
Open access
LLLing Lee
Ling Lee
LALaura De Angelis
Laura De Angelis
EBErica Barclay
Erica Barclay
NTNina Tahhan
Nina Tahhan
KSKathryn Saunders
Kathryn Saunders
TFTimothy R. Fricke
Timothy R. Fricke
There are an increasing number of effective myopia control options available; however, their financial impacts are unclear. We estimated lifetime costs of myopia under 5 scenarios in France and the United Kingdom (UK): traditional myopia management (single vision correction), low-dose atropine, anti-myopia spectacles, anti-myopia soft contact lenses, and orthokeratology. Model-based cost estimate. Each modeled scenario began with an 8-year-old child presenting with -0.75 DS. Natural progression data were used to determine the likelihood of possible refractive outcomes for children predicted to be at risk for faster and slower myopia progression until adulthood followed by an assumed exponential decay to zero progression by age 25 years. Societal care costs (direct and indirect) were collected from published sources, key informants, and informal surveys. Predicted progression rates for those at risk for slower and faster progression, costs, protocols, and risks were used to estimate and compare lifetime cost of myopia and its associated complications under each scenario. All future costs were discounted by 3% per year for sensitivity analysis. The main outcome measures were the lifetime cost of myopia, and cost ratio (myopia control cost divided by traditional care cost). Estimated lifetime cost of myopia using a traditional approach was US$32,492/US$22,606 for those predicted to experience faster/slower myopia progression in France, and US$48,170/US$29,664 in the UK. For those at risk for faster progression in France and the UK, cost ratios for the myopia control options ranged from 0.60 to 0.81, and 0.50 to 0.69, respectively. For those at risk for slower progression in France and the UK, the cost ratios ranged from 0.81 to 1.10, and 0.73 to 1.00, respectively. Female individuals incurred higher lifetime costs due to higher contact lens wear rates, prevalence of vision impairment, and longer life expectancy. Investment in myopia control during childhood in Europe likely reduces the total lifetime cost of myopia compared to traditional care via reduced refractive progression, need for complex lenses, and risk of pathology and vision loss. Children predicted to experience faster myopia progression derive the greatest economic advantage from myopia control.


11 September 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EMEmma L McConnell
Emma L McConnell
SBShelley A. Black
Shelley A. Black
JMJulie F. McClelland
Julie F. McClelland
LMLynne McKerr
Lynne McKerr
KDKarola Dillenburger
Karola Dillenburger
KSKathryn J. Saunders
Kathryn J. Saunders
To evaluate parent and teacher opinion of the provision of in-school eyecare and jargon-free written reporting of visual status for children in special educational settings. A nationally-agreed, in-school eyecare framework for children attending special schools which recommends a full eye examination, dispensing of spectacles and provision of a jargon-free written report of visual outcomes to parents and teachers, was provided to 200 children (mean age 10 years, 9 months; 70% male) attending a special school in the UK. The written ‘Vision Report’ detailed, in lay-language, results from the eye examination and provided practical advice to alleviate the impact of vision difficulties both at home and in the classroom. Following implementation of the framework, parents and teachers completed a feedback questionnaire to determine their opinion of the in-school eye examination and utility of the Vision Report. Parents of 123 participants returned a feedback questionnaire. Eighty-eight participants were represented by the 23 teachers who returned a questionnaire. The in-school eyecare was rated positively for children in special education by 82.4% of parents and 80.9% of teachers. Key benefits included the familiarity of the in-school setting (81.3% of parents and 100% of teachers agree), the convenience of the setting for parents (74.0% of parents and 100% of teachers agree), and the opportunity for teachers to speak directly to eyecare providers regarding a child’s visual needs (82.6% of teachers agree). The information provided by the Vision Report was deemed useful day-to-day by 78.3% of parents and 100% of teachers. The majority (80%) of teachers implemented classroom modifications suggested in the report, whereas only 47.9% of parents reported implementation of modifications at home. Provision of in-school eyecare is valued by parents and teachers of children in special education settings. Jargon-free, written reports of visual status are valued and utilised by parents and teachers. Further support is required to aid parents in implementing vision modifications at home.

11 June 2026 in BMJ
Verified
Journal Article
Open access
AAAugusto Azuara-Blanco
Augusto Azuara-Blanco
NLNicola S Logan
Nicola S Logan
EMEmma L McConnell
Emma L McConnell
SKStephanie Kearney
Stephanie Kearney
GKGaynor Kirk
Gaynor Kirk
MCMike Clarke
Mike Clarke
Objectives: To evaluate the efficacy and safety of low concentration atropine eye drops for reducing progression of myopia in children in the UK. Design: Multicentre, double masked, superiority, placebo controlled, randomised trial. Setting: National Health Service hospital eye services and academic institutions at five UK centres. Participants: 289 children aged 6-12 years with myopia between −0.50 and −10.0 dioptres (D). Participants were allocated in ratio of 2:1 to atropine or placebo. Interventions: One eye drop of preserved atropine 0.01% or placebo daily for two years. Main outcome measures: The primary outcome was spherical equivalent refractive error of both eyes measured by autorefractor under cycloplegia after two years. Secondary outcomes included change in axial length, best corrected distance and near visual acuity, reading speed, pupil diameter, spectacle correction, adverse event rates, quality of life, and tolerability. Outcomes were collected every six months. An electronic monitoring system was used to assess adherence. Results: 192 participants were included in the atropine group and 97 in the placebo group, with an average age of 9.3 years (standard deviation (SD) 1.7 years). 207 (72%) reported white ethnicity, 161 (56%) were girls, and the mean level of myopia was −2.87 D (SD 1.71 D). A total of 235 (81%) participants completed the study, with primary outcome data available for 230 (80%) participants: 151 (79%) in the atropine group and 79 (81%) in the placebo group. Atropine eye drops were more effective than placebo in reducing myopia progression (mean difference 0.33 D, 95% confidence interval (CI) 0.17 to 0.49 D, P<0.001). Prespecified subgroup analyses did not show differences according to age, ethnicity, sex, or severity of myopia. Changes in central axial length were significantly less in the atropine group versus placebo group: mean difference 0.14 mm (95% CI 0.07 to 0.21, P<0.001). There were no differences in other secondary outcomes, except pupil diameter, which was greater in the atropine group (0.36 mm, 95% CI 0.17, 0.55, P<0.001), and no differences in frequency of adverse events or in tolerability measures. No serious adverse events were related to the trial drugs. Conclusions: Low concentration atropine (0.01%) eye drops significantly reduced progression of myopia and were well tolerated compared with placebo in children in the UK. Trial registration: ISRCTN registry ISRCTN99883695 , ClinicalTrials.gov NCT03690089 .